Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.
Initially reserved for only the most complex of tasks, robots have become the status quo in many surgical indications.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.
